Extended Follow-up Results From CheckMate 274: Adjuvant Nivolumab in MIUC

Expert Matthew D. Galsky, MD, shares his perspective on follow-up results from CheckMate 274, which analyzed adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma.